This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Most Profitable Second Quarter Biotech Stocks

Amarin (AMRN): FDA acceptance (or rejection) of the Vascepa supplemental New Drug Application (sNDA) covering the larger "ANCHOR" trial population covering patients with mixed dyslipidemia in late April or early May. Acceptance is widely expected so this is an important (negative) catalyst for Amarin if FDA chooses to reject the sNDA or require pre-approval cardiovascular outcomes data. Amarin will also announce first quarter financial results (including the first reporting of Vascepa sales) in May.

Raptor Pharmaceuticals (RPTP): FDA approval decision for Procysbi in cystinosis on April 30.

Sangamo Biosciences (SGMO): Interim results from phase II studies of SB-728 in HIV will be presented at the American Society of Gene and Cell Therapy annual meeting, May 15-19.

Vertex Pharmaceuticals (VRTX): Data from the phase II study of next-generation cystic fibrosis "corrector" VX-661 in combination with Kalydeco.

NewLink Genetics (NLNK): Interim analysis of "IMPRESS" phase III trial of algenpantucel-L in resected pancreatic cancer.

AstraZeneca (AZN) and Rigel (RIGL): Top-line results from phase III studies of fostamatinib in rheumatoid arthritis.

Depomed (DEPO): FDA approval decision for Sefelsa in menopause on May 31. An FDA advisory panel in March voted against the drug's approval.

Biogen Idec (BIIB): The commercial launch of the multiple sclerosis pill Tecfidera.

Sucampo Pharmaceuticals (SCMP): FDA approval decision date for Amitiza in opioid-induced constipation on April 26.

Dendreon (DNDN): European approval decision on Provenge possible before end of the second quarter.

Valeant Pharmaceuticals (VRX): FDA approval decision for efinaconazole to treat toenail fungus infection on May 24.

GlaxoSmithKline (GSK): FDA approval decision for dabrafenib and trametinib in melanoma on June 3.

Aegerion Pharmaceuticals (AEGR): Potential European approval decision for Juxtapid in the second quarter.

Cancer drug stocks: Research abstracts for the American Society of Clinical Oncology (ASCO) annual meeting will be released on May 16, ahead of the actual meeting taking place May 31 through June 4. Relevant "ASCO" stocks include Ariad Pharmaceuticals (ARIA), Clovis Oncology (CLVS), Bristol-Myers Squibb (BMY), Pharmacyclics (PCYC), Spectrum Pharmaceuticals (SPPI), Amgen (AMGN), Infinity Pharmaceuticals (INFI - Get Report), Curis (CRIS) and Synta Pharmaceuticals (SNTA).

-- Reported by Adam Feuerstein in Boston.

Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.
2 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
ZGNX $9.48 -4.34%
ARNA $1.58 -0.32%
GILD $85.86 0.30%
INFI $5.11 -6.07%
SRPT $16.76 -2.67%


Chart of I:DJI
DOW 17,660.71 +9.45 0.05%
S&P 500 2,050.63 -0.49 -0.02%
NASDAQ 4,717.0940 -8.5450 -0.18%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs